NOVEMBER 2021 By Derek Bagley Special Delivery: A Look at New Modes of Diabetes Care Thanks to insulin’s discovery a century ago, diabetes is no longer the death sentence it once was. However, providing care can often be complicated for both in- and outpatient treatment regimens. Potential new models of diabetes care could help ease the burden of both the …
OCTOBER 07 2021 By galtalkstech.com Nausheen Moulana – Chief Technology Officer at Glytec “There are no silver bullets. Women, male allies, and employers need to work together to develop long-term sustainable solutions to recruit, develop, and retain women in the techforce”. Nausheen Moulana is the Chief Technology Officer at Glytec, the insulin management software company where she leads Product and …
Glytec Appoints Dr. Jordan Messler as Chief Medical Officer Experienced Physician and Glycemic Expert to Drive Safe Clinical Best Practices as Company Scales to Hospitals across the Country WALTHAM, MASS. (July 13, 2021) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced the appointment of Jordan Messler, MD, SFHM, FACP to Chief …
FEBRUARY 2021 Jordan Messler, MD, SFHM, FACP Why the Pandemic Sparked Improvement in Real-time Patient Dashboards The implementation of Electronic Health Records (EHR) following the government mandate more than a decade ago hasn’t always been easy, but it can be a game-changer when it comes to real-time patient data management. While EHRs drastically simplify the access to patient-specific data, information …
Glytec, the pioneer of digital therapeutics, has hired an expert team of clinicians to help clients drive and sustain full adoption of best practices in glycemic management.
Hospitals and health systems looking to establish brand dominance, competitive distinction and clinical excellence in diabetes care can turn to a team of experts at Glytec dedicated to helping facilitate full adoption of best practices.
She joins Glytec in a role that will tap her skills and experience leading operations and commercialization of emerging diabetes technologies and services.
Glytec, the pioneer of digital therapeutics and leader in insulin optimization, welcomes Paula LeClair as Executive Director and General Manager, Outpatient. In the diabetes industry, LeClair’s name is synonymous with transformation and innovation.
Furlong joins the company during a period of extraordinary growth and will assume a key leadership role in scaling commercial operations to meet evolving customer needs.
Glytec, the pioneer of personalized digital therapeutics, is pleased to announce the appointment of Ed Furlong as Chief Operating Officer. “We are thrilled to welcome Ed Furlong to our executive team,” says Glytec’s President and CEO, Bob Leonard. “Ed’s background in helping companies expand and diversify while sustaining strong financial health is ideally suited to our strategic imperatives, especially at this crucial juncture when demand for our products and services is increasing exponentially.”
Dr. Andrew S. Rhinehart to serve as Chief Medical Officer of Glytec.
Glytec, a clinical information technology company dedicated to improving insulin management and glycemic control for patients in hospitals and other care settings, today announced that Andrew S. Rhinehart, MD, FACP, CDE, BC-ADM, CDTC, has joined the company as the chief medical officer (CMO). In this role, Dr. Rhinehart will leverage his 20 years of clinical expertise to aid the development and innovation of Glytec’s suite of computerized, predictive dosing algorithms for IV, subcutaneous, and pediatric insulin dosing.
Melanie Mabrey to serve as Vice President of Clinical Practice.
Glytec, a clinical information technology company dedicated to improving insulin management and glycemic control for patients in hospitals and other care settings, is proud to welcome Melanie Mabrey, DNP, ACNP-BC, BC-ADM, FAANP, as the company’s Vice President of Clinical Practice. Mabrey will serve as the subject matter expert on current clinical best practices for standardizing insulin management across the continuum of care.